Familial hypercholesterolemia: An under-recognized but significant concern in cardiology practice

Clinical Cardiology

Volumn 37, Issue 2, 2014, Pages 119-125

  Foody, Joanne M ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATTITUDE OF HEALTH PERSONNEL; AWARENESS; BIOLOGICAL MARKERS; CARDIOLOGY; CHOLESTEROL; CLINICAL COMPETENCE; GENETIC PREDISPOSITION TO DISEASE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; HYPOLIPIDEMIC AGENTS; MUTATION; PHENOTYPE; PHYSICIANS; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 84893939616     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.22223     Document Type: Review

References (34)

1. Goldstein JL, Hobbs HH, Brown MS,. Familial hypercholesterolemia. In:, Scriver CR, Ellenson LH, Ellis NA, et al, eds. The Metabolic & Molecular Bases of Inherited Disease. 8th ed. New York, NY: McGraw-Hill; 2001: 2863-2913.
2. Hopkins PN, Toth PP, Ballantyne CM, et al. Familial hypercholesterolemias: prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011; 5: S9-S17.
3. Kraft HG, Lingenhel A, Raal FJ, et al. Lipoprotein(a) in homozygous familial hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2000; 20: 522-528. (Pubitemid 30086112)
4. Marais AD,. Familial hypercholesterolaemia. Clin Biochem Rev. 2004; 25: 49-68.
5. American College of Cardiology CardioSurve. Familial hypercholesterolemia cardiologist and patient needs assessment [purchased report]. Survey conducted November 2011.
6. American College of Cardiology. Familial hypercholesterolemia: cardiologist and patient perspectives. CardioSurve Newsletter. July 2012; 2:4. http://www.cardiosource.org/News-Media/Publications/CardioSurve.aspx. Accessed July 17, 2013.
7. Vella A, Pineda AA, O'Brien T,. Low-density lipoprotein apheresis for the treatment of refractory hyperlipidemia. Mayo Clin Proc. 2001; 76: 1039-1046. (Pubitemid 32946016)
8. Goldberg AC, Robinson JG, Cromwell WC, et al. Future issues, public policy, and public awareness of familial hypercholesterolemias: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011; 5: S46-S51.
9. Kwiterovich PO Jr, Fredrickson DS, Levy RI,. Familial hypercholesterolemia (one form of familial type II hyperlipoproteinemia). A study of its biochemical, genetic and clinical presentation in childhood. J Clin Invest. 1974; 53: 1237-1249.
10. Goldberg AC, Hopkins PN, Toth PP, et al. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011; 5: 133-140.
11. O'Neill FH, Patel DD, Knight BL, et al. Determinants of variable response to statin treatment in patients with refractory familial hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2001; 21: 832-837. (Pubitemid 32448775)
12. Santos RD, Miname MH, Martinez LR, et al. Non-invasive detection of aortic and coronary atherosclerosis in homozygous familial hypercholesterolemia by 64 slice multi-detector row computed tomography angiography. Atherosclerosis. 2008; 197: 910-915. (Pubitemid 351417893)
13. Pijlman AH, Juijigen R, Verhagen SN, et al. Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in the Netherlands. Atherosclerosis. 2010; 209: 189-194.
14. Haase A, Goldberg AC,. Identification of people with heterozygous familial hypercholesterolemia. Curr Opin Lipidol. 2012; 23: 282-289.
15. Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010; 376: 1670-1681.
16. Holmes DT, Schick BA, Humphries KH, et al. Lipoprotein(a) is an independent risk factor for cardiovascular disease in heterozygous familial hypercholesterolemia. Clin Chem. 2005; 51: 2067-2073. (Pubitemid 41532622)
17. Clarke R, Peden JF, Hopewell JC, et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med. 2009; 361: 2518-2528.
18. Nemati MH, Astaneh B, Joubeh A,. Triple coronary artery bypass graft in a 10-year-old child with familial hypercholesterolemia. Gen Thorac Cardiovasc Surg. 2009; 57: 94-97.
19. Widhalm K, Binder CB, Kreissl A, et al. Sudden death in a 4-year-old boy: a near-complete occlusion of the coronary artery caused by an aggressive low-density lipoprotein receptor mutation (W556R) in homozygous familial hypercholesterolemia. J Pediatr. 2011; 158: 167.
20. Raal FJ, Pilcher GJ, Panz VR, et al. Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy. Circulation. 2011; 124: 2202-2207.
21. Kawaguchi A, Yutani C, Yamamoto A,. Hypercholesterolemic valvulopathy: an aspect of malignant atherosclerosis. Ther Apher Dial. 2003; 7: 439-443. (Pubitemid 37082034)
22. Marks D, Thorogood M, Neil HA, et al. A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia. Atherosclerosis. 2003; 168: 1-14. (Pubitemid 36559596)
23. Oosterveer DM, Vermissen J, Yazdanpanah M, et al. Differences in characteristics and risk of cardiovascular disease in familial hypercholesterolemia patients with and without tendon xanthomas: a systematic review and meta-analysis. Atherosclerosis. 2009; 207: 311-317.
24. Ang M, Wong W, Park J, et al. Corneal arcus is a sign of cardiovascular disease, even in low-risk persons. Am J Ophthalmol. 2011; 152: 864-871.
25. Liyanage KE, Burnett JR, Hooper AJ, et al. Familial hypercholesterolemia: epidemiology, Neolithic origins and modern geographic distribution. Crit Rev Clin Lab Sci. 2011; 48: 1-18.
26. Williams RR, Hunt SC, Schumacher MC, et al. Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics. Am J Cardiol. 1993; 72: 171-176. (Pubitemid 23205873)
27. World Health Organization Familial Hypercholesterolemia Consultation Group. Familial hypercholesterolemia. Report of a WHO consultation. Geneva, Switzerland: World Health Organization; 1998.
28. Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific Steering Committee on behalf of the Simon Broome Register Group. BMJ. 1991; 303: 893-896.
29. Civeira F., Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. Atherosclerosis. 2004; 173: 55-68. (Pubitemid 38224196)
30. Robinson JG, Goldberg AC,. Treatment of adults with familial hypercholesterolemia and evidence for treatment: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011; 5: S18-S29.
31. Ito MK, McGowan MP, Moriarty PM,. Management of familial hypercholesterolemias in adult patients: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011; 5: S38-S45.
32. Juxtapid (lomitapide) [package insert]. Cambridge, MA: Aegerion Pharmaceuticals; 2013.
33. Kynamro (mipomersen sodium) injection [package insert]. Cambridge, MA: Genzyme Corporation; 2013.
34. Dorsch MF, Lawrance RA, Durham NP, et al. Familial hypercholesterolaemia is underdiagnosed after AMI. BMJ. 2001; 322: 111.